ImmunityBio, Inc.IBRXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

5 analysts·Limited coverage

100%

Rating Distribution

Strong Buy

00%

Buy

5100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 12% higher.

Bear Case

$7.00

+12%

Consensus

$7.00

+12%

Bull Case

$7.00

+12%

Price Range5 analysts

Low

Consensus

High

$7.00

Current Target

Current Price

$6.25

Upside to Target

$0.75

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.28(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+149.49%

EPS—

FY2028

Rev+98.12%

EPS—

FY2029

Rev+83.40%

EPS+168.87%

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:+1.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 20, 2026Piper Sandler

ImmunityBio price target raised to $7 from $5 at Piper Sandler

Target:$7.00

+26.8%from $5.52

Jan 10, 2025BTIG

ImmunityBio initiated with a Buy at BTIG

Target:$6.00

+147.9%from $2.42

Aug 3, 2022Jefferies

Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline

Target:$8.00

+93.9%from $4.13

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance